MARCH 2017: *UPDATE ON PROTOCOL for #NCT02060188
The "nivo + ipi + cobi" trial specific for mCRC has added two new arms: with a new combination for MSS:
* a new arm for MSS-CRC:
Nivolumab (Nivo) + Daratumumab (Cohort C6).
Daratumumab is an anti-CD38 monoclonal antibody (FDA approved for multiple myeloma, trade name Darzalex).
* a new arm for for MSI-High CRC:
Nivolumab (Nivo) + BMS-986016 (an anti-LAG-3 antibody, experimental) (Cohort C5)
https://clinicaltrials.gov/ct2/show/study/NCT02060188
Let's remember that this trial (one of the first immuno trial for mCRC) used to be, first, only nivolumab (aPD-1) + ipilimumab (anti CTLA-4), both MS status, and only past October added one arm for MSS: added Cobimetinib, a MEK inhibitor, to nivo and ipi.
The trial also changed its name from
"A Study of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Colon Cancer (CheckMate 142)"
to the current
"An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate 142)"